Key result
Zofenopril and other ACE inhibitors with high tissue bioavailability offer antihypertensive and cardioprotective benefits, including prevention of left ventricular hypertrophy.
Why the study?
Does zofenopril improve cardioprotective outcomes in patients with arterial hypertension after acute myocardial infarction?
Does zofenopril improve cardioprotective outcomes in patients with arterial hypertension after acute myocardial infarction?
Zofenopril offers specific cardioprotective benefits, such as preventing left ventricular hypertrophy, due to its high tissue bioavailability in post-MI hypertensive patients.
May support zofenopril for LVH prevention in hypertension; leaves open randomized confirmation of post-MI benefits.
The article provides an overview of the main comparative studies of antihypertensive efficacy and cardioprotective characteristics of zofenopril. We showed the information about the benefits of the drugs with higher tissue bioavailability preventing left ventricular hypertrophy and increasing its stiffness, because number of drugs possessing antiatherosclerotic and antiischaemic effects. The results of the studies, revealing the characteristics of action of these drugs class, will extend the capabilities of medical practitioners in the treatment of patients suffering from AH after acute myocardial infarction, associated with angina.
No takes yet. Share an insight, caveat, or question.
A A Kirichenko (2014) conducted a review in Arterial hypertension after acute myocardial infarction associated with angina. Zofenopril was evaluated. Zofenopril and other ACE inhibitors with high tissue bioavailability offer antihypertensive and cardioprotective benefits, including prevention of left ventricular hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: